Stay updated on Pyrotinib Combo in HR+/HER2- Clinical Trial
Sign up to get notified when there's something new on the Pyrotinib Combo in HR+/HER2- Clinical Trial page.

Latest updates to the Pyrotinib Combo in HR+/HER2- Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference13%

- Check33 days agoChange Detected- Updated recruitment status and study title to reflect a newer version (v3.1.0) and a current date (2025-09-25). - Indicates progression to Active, not recruiting, and a renamed study: 'Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer' from the prior title. - Removed older date (2024-11-04) and older revision (v3.0.2) to align with the new revision (v3.1.0).SummaryDifference5%

- Check47 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2, and the 'Back to Top' link was removed.SummaryDifference0.8%

- Check54 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.SummaryDifference0.8%

- Check61 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location details, while removing specific state, country, and city information.SummaryDifference7%

- Check76 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.3%

Stay in the know with updates to Pyrotinib Combo in HR+/HER2- Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pyrotinib Combo in HR+/HER2- Clinical Trial page.